George Abraham, MD
Pulmonary Disease · Jackson, MSNPI 1518052257
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Intuitive Surgical at 39.3% of the total. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $39.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$902
- Pfizer$761
- plus $6K from 38 others
What the payments were for
- Consulting fees$1,8808%
- Speaking & faculty fees$3,75016%
- Travel & lodging$1,1445%
- Food & beverage$13,06057%
- Education$3,01613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$4,200
- ION$3,000
- TAGRISSO$1,981
- Da Vinci Surgical System$1,114
- TEZSPIRE$250
- DUPIXENT$209
- TRELEGY ELLIPTA$125
- NUCALA$125
- Impella$120
- BREZTRI$100
How this compares
$22,849 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $260,381 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $55,810 |
| Dupixent PenDupilumab | 12 | $41,877 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $34,488 |
| Spiriva RespimatTiotropium Bromide | 33 | $24,649 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $16,326 |
| Spiriva HandihalerTiotropium Bromide | 19 | $10,114 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $9,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,780 |
| Roflumilast | 34 | $5,773 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $4,646 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,336 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,507 |
| Pulmicort FlexhalerBudesonide | 12 | $2,419 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $1,042 | $285,03055 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,642 | $103,608201 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Pulmicort Flexhaler | $3,325 | $26,52564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.